Gene-Editing breakthrough: CRISPR stem cell therapy targets sickle cell disease

NCT ID NCT04774536

First seen Apr 20, 2026 · Last updated May 10, 2026 · Updated 4 times

Summary

This early-stage trial tests a one-time infusion of the patient's own blood stem cells, which have been corrected using CRISPR gene editing to fix the sickle cell mutation. The goal is to reduce painful blockages in blood vessels and other complications. Nine people aged 12 to 35 with severe sickle cell disease will receive the treatment and be monitored for safety and effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UCSF Benioff Children's Hospital

    RECRUITING

    Oakland, California, 94609, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of California, Los Angeles

    RECRUITING

    Los Angeles, California, 90095, United States

    Contact Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.